night-sky-stars.jpeg
PICTURE.jpg
PastedGraphic-1.png
DOCTORS.jpg
night-sky-stars.jpeg

Introducing the stentrode™


THE FIRST ENDOVASCULAR NEURAL INTERFACE

 

SCROLL DOWN

Introducing the stentrode™


THE FIRST ENDOVASCULAR NEURAL INTERFACE

 

Synchron, a US based neural interface company, is developing the STENTRODE™, the world’s first endovascular electrode array.

The STENTRODE is a minimally invasive implantable device designed to interpret signals from the brain.

The STENTRODE™ may ultimately help diagnose and treat a range of brain pathologies, such as paralysis, epilepsy and movement disorders. It has the potential to fundamentally change the way of life for patients with a wide range of neurological disorders.

U.S. Defense Advanced Research Projects Agency (DARPA) provided seed funding for the development of the STENTRODE™ technology.

Synchron is currently preparing for a pilot clinical trial of the STENTRODE to evaluate the safety and feasibility of the device to enable patient directed brain control over mobility-assist devices.

PICTURE.jpg

Applications


Enabling robotic-human augmentation for the treatment of paralysis.

Applications


Enabling robotic-human augmentation for the treatment of paralysis.

Screen Shot 2016-10-11 at 12.43.13 PM.png

The STENTRODE is the world’s first endovascular neural interface.

The STENTRODE™ is a minimally invasive implantable brain device that could help paralyzed patients achieve direct brain control of assisted technologies.

The proprietary new technology platform is being developed for patients
with paralysis to facilitate control of external devices such as robotic limbs, computers and exoskeletons by translating brain activity.

The STENTRODE may ultimately help diagnose and treat a range of brain pathologies, such as epilepsy and Parkinson’s disease.

PastedGraphic-1.png

MEDIA


A revolutionary technology pushing the boundaries for paralyzed patients.

MEDIA


A revolutionary technology pushing the boundaries for paralyzed patients.

 

Barack obama on THE stentrode DEVICE

US President Barack Obama talks about the technology that has the potential to transform the lives of people with disabilities.

MOVING WITH THE POWER OF THOUGHT

A device the size of a matchstick, implanted next to the brain’s motor cortex, could one day help paralysed people move their limbs.

 
DOCTORS.jpg

Partners


Synchron EXISTS WITHIN A VAST NETWORK SPANNING THE NEUROVASCULAR, NEURAL INTERFACE AND ROBOTICS INDUSTRIES.

Partners


Synchron EXISTS WITHIN A VAST NETWORK SPANNING THE NEUROVASCULAR, NEURAL INTERFACE AND ROBOTICS INDUSTRIES.

Synchron has partnered with numerous world-leading organizations spanning the fields of medicine, engineering and bionics.

CEO and Founder, Dr Tom Oxley, is the lab head of the Vascular Bionics Laboratory, Department of Medicine (Royal Melbourne Hospital), University of Melbourne. Dr Oxley led a team of 39 academics across 16 departments to publish a seminal paper in
Nature Biotechnology in February, 2016.

Over a number of years, Synchron has progressed relationships with strategic multinational device companies, innovative Global manufacturers and established a commercialization infrastructure within the Silicon Valley Med tech industry.